Clinical Trial Update: Temsirolimus in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of temsirolimus in refractory or recurrent ovarian epithelial, fallopian tube, or primary peritoneal cancer; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• Temsirolimus (temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-11-20